CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.Patient-reported outcomes from the randomized IMbrave050 trial presented at ASCO Annual Meeting suggest that an adjuvant regimen of atezolizumab plus
A partnership between health care systems along the U.S.-Mexico border led to clinically meaningful improvement in survival outcomes among children with acute lymphoblastic leukemia, study results showed. The analysis of the cancer treatment training and access initiative — scheduled for presentation at ASCO Annual Meeting — revealed a significant increase in 5-year OS among children
Treatment with luspatercept vs. epoetin alfa nearly doubled the number of patients with lower-risk myelodysplastic syndrome who no longer required red blood cell transfusions for anemia, results of the phase 3 COMMANDS trial showed.The findings, scheduled for presentation at ASCO Annual Meeting, showed luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) — an erythroid maturation agent
Treatment with exagamglogene autotemcel conferred clinically meaningful increases in fetal hemoglobin and total hemoglobin levels among patients with beta-thalassemia and sickle cell disease, results of two pivotal studies showed. The latest follow-up data from the CLIMB THAL-111 and CLIMB-SCD-121 trials — presented at American Society for Gene & Cell Therapy Annual Meeting —
An investigational chimeric antigen receptor T-cell therapy demonstrated successful expansion and antitumor targeting among younger patients with advanced acute myeloid leukemia, results of the phase 1 PLAT-08 trial showed. The findings — presented at American Society for Gene & Cell Therapy Annual Meeting — demonstrated the feasibility and safety of pharmacologically controlled